The 18 CRCT

T2i : Anti-tumour immunity and immunotherapy

Maya AYYOUB, Jean-Pierre DELORD
and 16 collaborators

Deciphering the molecular and cellular mechanisms of tumour sensitivity/resistance to immunotherapy in order to design combined therapies capable of overcoming resistance.


SIGNATHER : Cell Signalling, Oncogenesis and Therapeutics

Gilles FAVRE, Ollivier SORDET
and 29 collaborators

To understand the molecular mechanisms of deregulation of signalling pathways involved in cell proliferation and survival, in order to enable the development of new cancer treatments, through transfer to the clinic in particular in lung cancers.


MELASPHINX : Ceramide metabolism in melanoma: from basic mechanisms to immunotherapy

Bruno SEGUI, Nathalie ANDRIEU
and 21 collaborators

Targeting the metabolism of ceramide and its derivatives to prevent tumour progression and overcome resistance to anti-cancer drugs, cytokines and immune cells.


RNAreg : RNA-Binding Proteins and Genotoxic Stress

and 14 collaborators

Understanding the cellular and molecular mechanisms involved in the post-transcriptional expression of key genes in the response to genotoxic and immunomodulatory treatments: from the RNA molecule to the patient.


MICROPANC : Microenvironnement and Therapeutic Resistance in Pancreatic Neoplasms

and 18 collaborators

To understand how the tumour microenvironment, and more specifically cancer-associated fibroblast populations, contribute to the heterogeneity of pancreatic tumours and organise their resistance to therapies, in order to propose combinations of drugs that co-target this microenvironment in addition to targeting tumour cells.


R’n Blood : RNA Biology in Hematologic Tumors

Stéphane Pyronnet, Fabienne MEGGETTO
and 16 collaborators

Understanding RNA-dependent regulatory mechanisms (mRNAs and non-coding RNAs such as lncRNAs, miRNAs and circRNAs) in normal and tumour haematopoiesis and in treatment resistance


NoLymIT : New Immunotherapies Against Lymphoma

and 21 collaborators

Through the study of the immune component of the microenvironment in B lymphoma and Chronic Lymphocytic Leukemia (CLL), the team aims to characterize immune escape mechanisms as well as new therapeutic targets using single-cell sequencing techniques implemented with innovative bioinformatics tools, sophisticated in vitro culture imaging techniques and 3D modeling.


ImPACT : Innovation in pancreatic cancer therapy

Pierre Cordelier
and 21 collaborators

To characterise the heterogeneity of pancreatic cancer in order to define new diagnostic and therapeutic approaches to improve the management of patients with this cancer.


RADOPT : Optimising radiotherapy: from molecular signalling pathways to clinical trials

Elizabeth Cohen-Jonathan Moyal
and 22 collaborators

To optimise radiotherapy in the management of patients with glioblastoma (GBM):  The studies carried out concern the biological mechanisms of radioresistance, the optimisation of the definition of the target to be irradiated and the delivery of the dose on complex volumes in order to decipher the mechanisms of radioresistance, to validate targets of interest to be targeted by specific inhibitors which are then evaluated in clinical trials combining via artificial intelligence approaches all the multi-data of clinical parameters, biological markers, imaging and physics in the prediction of the therapeutic response studied.


INOV : Cholesterol Metabolism and Therapeutic Innovations

and 15 collaborators

Understanding the role of cholesterol metabolism in controlling tumour progression and resistance to therapy, particularly in breast cancer, thyroid cancer and melanoma


GENIM : Genomic and Immunology of myeloma

and 24 collaborators

This team is fully dedicated to the understanding and therapeutic targeting of multiple myeloma, an incurable hematological malignancy affecting the bone marrow. More specifically, our team aims to study the impact of genomic and immune factors on the development of myeloma and the response to treatment.


DIAD : Dose Individualisation of Anticancer Drugs

Etienne Chatelut
and 17 collaborators

This team is interested in the pharmacokinetics of anticancer drugs: the study of their fate in the body and their elimination. The aim is to better adapt the dose to each patient.


IGAALD : Impact of genetic alterations on acute leukemia development

Eric Delabesse
and18 collaborators

The activity of this team is part of a translational research thanks to a hospital component that allows, in addition to diagnosis, to search for molecular causes (mutations) in patients suffering from leukemia, and a basic research component that models these causes in cells or in mouse models in order to find new therapeutic targets.


SigDYN : Integrated cellular signalling and PI3K isoforms

and 11 collaborators

This team uses innovative technologies to study the roles of PI3K isoforms in the intercellular dialogue in order to propose new therapies that block the signalling networks activated in cancers, and thus block tumour progression. Our research targets pancreatic and ovarian cancers, two cancers with a very poor prognosis.


METAML : Metabolism and Therapeutic Resistance In Acute Myeloid Leukemia

Jean-Emmanuel SARRY / Carine JOFFRE
and 31 collaborators

Acute myeloid leukaemias are characterised by a high relapse rate in response to treatments, due to the development of resistance to therapies. The aim of the METAML team is to study the mechanisms of adaptation and metabolic reprogramming underlying this resistance in order to develop new therapeutic strategies to eradicate resistant leukaemia cells and prevent relapse.


ONCOSARC – Oncogenesis of sarcomas

Frédéric CHIBON
and 10 collaborators

Understanding the chromosomal mechanisms of oncogenesis of pleomorphic sarcomas. The results of the work are constantly envisaged in a context of transfer towards an improvement in patient care thanks to this team, half of which is composed of clinicians (pathologists, medical oncologists, surgeons).


DynAct : Molecular dynamics of Lymphocyte Interactions

and 13 collaborators

To use experimental and computational tools to decipher intercellular communication at the immunological synapse between cells of the human immune system in order to better understand immune responses in cancer patients and, in perspective, to contribute to the improvement of immunotherapeutic strategies against cancer


NetB(IO)² : Network Biology for Immuno-oncology

and 10 collaborators

Study of the epigenomic variability of immune cells and cellular interactions in tumours using multi-omics (single cell, spatial transcriptomics), artificial intelligence and mathematical modelling approaches

Centre de Recherches en Cancérologie de Toulouse

Toulouse Cancer Research Center (Oncopole)

Toulouse – FR

Contact us

+33 5 82 74 15 75

Want to join
the CRCT team ?

Pin It on Pinterest